Business Context and Reporting Period
Company: Kestra Medical Technologies, Ltd. (KMTS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended April 30, 2026
Business Overview: Kestra is a commercial-stage wearable medical device company focused on the Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The device monitors heart rhythms and delivers defibrillation therapy for patients at risk of sudden cardiac arrest. The company operates primarily in the U.S., billing third-party payors (Medicare, Medicaid, private insurers) for device leases.
Key Financial Metrics
| Metric | Fiscal Year 2026 | Fiscal Year 2025 |
|---|---|---|
| Revenue | $95.1 million | $59.8 million |
| Gross Profit | $48.9 million | $24.2 million |
| Gross Margin | 51.4% | 40.5% |
| Operating Loss | $(134.7) million | $(106.4) million |
| Net Loss | $(131.6) million | $(113.8) million |
| Cash, Cash Equivalents, and Investments | $262.2 million | $237.6 million |
| Accumulated Deficit | $(651.9) million | $(520.2) million |
| Long-Term Debt (Net) | $42.6 million | $41.1 million |
Note: The filing text indicates a subsequent refinancing event in July 2026 where the prior term loan was repaid and a new facility was established.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 59% year-over-year, driven primarily by a 58% increase in the number of patients using the ASSURE WCD.
- Margin Expansion: Gross margin improved from 40.5% to 51.4%. This was driven by a decrease in cost of revenue per patient (down 18%) due to better utilization of the rental equipment pool, lower disposable costs from volume, and an accounting change extending the useful life of medical rental equipment.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 43% to $164.1 million, largely due to personnel costs associated with expanding the commercial team (sales force grew from 80 to 130 representatives) and public company compliance costs. R&D expenses increased 24% to $19.5 million.
- Capital Raises: The company completed an IPO in March 2025 (net proceeds ~$215.8 million) and a follow-on public offering in December 2025 (net proceeds ~$149.3 million).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes existing cash, investments, and operating cash flows are sufficient to fund operations for at least the next 12 months.
- Strategy: Focus remains on capturing U.S. market share, expanding the sales force, and pursuing international regulatory approvals (CE Mark) for Western Europe within the next three years.
- Product Innovation: Announced the "Enhanced ASSURE Detection Algorithm" in April 2026 to reduce false alarms. Collaborating with Biobeat Technologies to integrate cuffless blood pressure monitoring.
Risks and Contingencies
- Internal Controls: The company identified material weaknesses in internal control over financial reporting as of April 30, 2026. Issues included insufficient resources in accounting/IT, lack of controls for non-routine transactions, and deficiencies in IT general controls (change management, user access). Remediation is ongoing.
- Profitability: The company has a history of net losses and no assurance of achieving profitability. Continued investment in sales and commercial infrastructure is expected to increase expenses.
- Reimbursement: Revenue is highly dependent on third-party payor reimbursement rates and coverage policies. Changes in Medicare or private payor policies could materially impact financial results.
- Competition: The primary competitor is ZOLL Medical (LifeVest). A new entrant received FDA approval for an adhesive-based defibrillator in May 2025.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress and timeline for remediating the identified material weaknesses in internal controls over financial reporting.
- Debt Covenants: Review the terms of the new Term Loan facility entered into in July 2026, specifically the minimum liquidity covenant ($20 million) and revenue milestones required for additional tranches.
- Reimbursement Rates: Monitor Medicare and private payor reimbursement rates for HCPCS code K0606 and any potential changes in coverage policies.
- False Alarm Rates: Validate the clinical impact of the new "Enhanced ASSURE Detection Algorithm" on patient compliance and false alarm reduction compared to competitors.
- International Expansion: Track the timeline and costs associated with obtaining CE Mark approval for European market entry.